Does the Asian population differ from the western populations in regards to gastric cancers
Manish Shah, MD of Weill-Cornell Medical Center, NYC answers the question does the Asian population differ from the western populations in regards to gastric cancers at ASCO GI 2016.
Tom Beer, MD, describes use of DNA repair markers when determining treatment of prostate cancer
Dr. Beer, Professor of Medicine, Oregon Health Sciences University, describes the use of DNA repair markers when determining treatment of prostate cancer patients
Tilak Sundaresan, MD, regarding the results of the TAPUR study and its importance to physicians
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, regarding the results of the TAPUR study presented at ASCO GU 2020 and its importance to physicians
Tilak Sundaresan, MD, determines whether to automatically test for the BRAF mutation in patients
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, determines whether to automatically test for the BRAF mutation in patients and how this mutation affects treatment of colorectal patients
Tilak Sundaresan, MD, shares how "sided-ness" affects the use of EGFR inhibitors in CRC treatment
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, shares how the recent clinical studies concerning "sided-ness" affects the use of EGFR inhibitors in the treatment of colorectal cancer
Tilak Sundaresan, MD, discusses combining regorafenib and checkpoint inhibitors in advanced CRC
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, provided perspective on the combination of regorafenib and checkpoint inhibitors in advanced colorectal cancer
Tilak Sundaresan, MD, elaborates on the influence of cell free DNA when managing CRC patients
Dr. Sundaresan, Assistant Chief, Kaiser Permanente San Francisco Medical Center, elaborates on the influence of cell free DNA when making decisions on the management of colorectal cancer patients
Crystal Denlinger, MD, offers opinion on checkpoint inhibitors being used in anal cancer management
Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, offers opinion regarding checkpoint inhibitors being used in the management of anal cancer
Crystal Denlinger, MD, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI
Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, discusses quality of life analysis in the IMBRAVE study presented at ASCO GI 2020
Crystal Denlinger, MD, regarding cell free DNA tests and their influence on the treatment of CRC patients
Crystal Denlinger, MD, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, regarding cell free DNA tests and how they can influence decision making when treating colorectal cancer patients
Crystal Denlinger, MD, comments on the use of fitness trackers in regards to management of CRC
Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, comments on the use of fitness trackers to assess activity level and toxicities regarding the management of colorectal cancer patients
David H Ilson, MD, elaborates on updated data from the BEACON study presented at ASCO GI 2020
Dr. Ilson, Memorial Sloan Kettering Cancer Center, elaborates on updated data regarding the BEACON study presented this year at ASCO GI
David H Ilson, MD, on the JAVELIN 100 study and the need for quick responses and immunotherapy in GE
Dr. Illson, Memorial Sloan Kettering Cancer Center, explains the outcomes of the JAVELIN 100 study presented at ASCO GI 2020 and how it relates to the need for quick responses and immunotherapy in gastroesophageal cancer patients
Zev Wainberg, MD, on the role of pembrolizumab for MSI high CRC patients and its use in therapy
Dr. Wainberg, Co-Director UCLA GI Oncology Program, Ronald Reagan UCLA Medical center, discusses the appropriate role of pembrolizumab when treating MSI high colorectal cancer patients
Zev Wainberg, MD, explains appropriate therapy following initial treatment for GI & GE tumors
Dr. Wainberg, Co-director UCLA GI Oncology Program, Ronald Reagan UCLA Medical Center, explains maintenance therapy that is appropriate following initial treatment for gastric and gastroesophageal tumors
Zev Wainberg, MD, shares the best way to combine checkpoint inhibitors in gastric and GE tumors
Dr. Wainberg, Co-director UCLA GI Oncology Program, Ronald Reagan UCLA Medical Center, shares the best method to combine checkpoint inhibitors in gastric and gastroesophageal junction tumors
Zev Wainberg, MD, on the line of therapy for checkpoint inhibitors in gastric and GI cancers
Dr. Wainberg, Co-director UCLA GI Oncology Program, Ronald Reagan UCLA Medical Center, elaborates on the optimal line of therapy for checkpoint inhibitors in gastric and gastroesophageal junction cancer patients.
Hani Babiker, MD, on tumor treatment field combinations in the management of GI malignancies
Dr. Babiker, Director, University of Arizona Cancer Center, explains tumor treatment fields combined with other modalities in the management of gastrointestinal malignancies.
Hani Babiker, MD, defines tumor treatment fields as well as the mechanism of action
Dr. Babiker, Director, The University of Arizona Cancer Center, defines tumor treatment fields as well as the mechanism of action
Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment
Dr. Kaseb, Professor, The University of of Texas M.D. Anderson Cancer Center, elaborates on the differentiation of levatinib vs cabozantinib when selecting a therapy for treatment of first line treatment of HCC
Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC
Dr. Kaseb, Professor, The University of Texas M.D. Anderson Cancer Center, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC
Ahmed Kaseb, MD, shares the role of checkpoint inhibitors when alone and combined with anti-CTLA4
Dr. Kaseb, Professor, The University of Texas M.D. Anderson Cancer Center, shares the role of checkpoint inhibitors when alone, and also when combined with anti-CTLA4 regarding the management of HCC patients.
Irvin Modlin, MD, explains the reason NETest is more effective than a biomarker test such as CGA
Dr. Modlin, Professor Emeritus, Yale School of Medicine, explains the reason NETest is more effective then mono-analyte biomarker tests such as CGA
Irvin Modlin, MD, describes whether NETest replaces or supplements imaging
Dr. Modlin, Professor Emeritus, Yale School of Medicine, describes whether NETest replaces or supplements imaging
Irvin Modlin, MD, offers opinion of NETest and whether it is cost prohibitive
Dr. Modlin, Professor Emeritus, Yale School of Medicine, offers opinion of NETest and whether it is cost prohibitive
Irvin Modlin, MD, explains the specificity and sensitivity of the NETest
Dr. Modlin, Professor Emeritus, Yale School of Medicine, explains specificity and sensitivity of NETest
Irvin Modlin, MD, shares importance of NETest, requirement for testing, and where to send results
Dr. Modlin, Professor Emeritus, Yale School of Medicine, shares the importance of NETest, what is required to preform the testing, and where the results are sent
Nevena Damjanov, MD, shares personal opinion of treatment of patient with a high expression of AFP
Dr. Damjanov, Director of Gastrointestinal Oncology, shares personal opinion regarding treatment of a patient with a high expression of AFP and the possibility of greater sensitivity to VEGF2 inhibitors
Eileen O'Reilly, MD, shares outcomes of the POLO study and its importance to physicians
Dr. O'Reilly, Winthrop Rockefeller Endowed Chair in Medical Oncology, Memorial Sloan Kettering Cancer Center, shares outcomes of the POLO study and its importance to physicians
Eileen O'Reilly, MD, describes how physicians should test for BRCA in pancreatic cancer patients
Dr. O'Reilly, Winthrop Rockefeller Endowed Chair in Medial Oncology, Memorial Sloan Kettering Cancer Center, shares opinion on how physicians should test for BRCA in pancreatic cancer patients
Sam Klempner, MD, describes the role of Cyramza in the treatment of GR junction cancers
Dr. Klempner, Assistant Professor, Harvard Medical School, describes the role of Cyramza (ramucirumab) in the treatment of gastroesophageal junction cancers
Sam Klempner, MD, considers promising approaches to therapy in development for upper GI malignancies
Dr. Klempner, Assistant Professor of Medicine, Harvard Medical School, considers promising approaches to therapy in the development of upper gastrointestinal malignancies
Manish Shah, MD, discusses avelumab's effectiveness based on results from the JAVELIN 100 study
Dr. Shah, Director, Weill Cornell Medicine, discusses the effectiveness of avelumab as maintenance therapy in gastric cancers based on results of the JAVELIN 100 study.
Manish Shah, MD, explains whether levatinib can be combined with I-O to treat and manage GI cancer
Dr. Shah, Director, Weill Cornell Medicine, explains whether levatinib is able to be combined with I-O to treat and manage gastrointestinal cancer patients
Manish Shah, MD, describes BRAF testing tactics and how it affects treatment of CRC patients
Dr. Shah, Director, Weill Cornell Medicine, describes the importance of BRAF testing tactics and how it affects treatment of colorectal cancer patients.
Irvin Modlin, MD, on when to use NETest clinically and situations it has clinical utility
Dr. Modlin, Professor Emeritus, Yale School of Medicine, elaborates on when to NETest clinically and situations in which it has clinically utility
Daniel Catenacci, MD, on the role of margetuximab to improve treatment outcomes of GI cancers
Dr. Catenacci, Associate Professor, The University of Chicago Medical Center and Biological Sciences, shares thoughts on how the role of margetuximab will evolve to improve outcomes in the treatment of esophageal and gastric cancers
Daniel Catenacci, MD, shares opinion on the role of checkpoint inhibitors for GI malignancies
Dr. Catenacci, Associate Professor, The University of Chicago Medical Center and Biological Sciences, shares opinion on whether checkpoint inhibitors have a promising role in the treatment of first line metastatic upper gastrointestinal malignancies
Philip Philip, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas
Dr. Philip, Clinical Professor of Oncology, Wayne State University of Medicine, shares perspective on the phase 2 study comparing gemcitabine/cisplatin with or without veliparib in germ-line pancreatic cancer patients
Philip Philip, MD, shares opinion on treatment of a BRCA+ pancreatic cancer patient
Dr. Philip, Clinical Professor of Oncology, Wayne State University of Medicine, shares opinion regarding his typical treatment of BRCA+ pancreatic cancer patients
Philip Philip, MD, explains how physicians should test for BRCA in pancreatic cancer patients
Dr. Philip, Clinical Professor of Oncology, Wayne State University of Medicine, provides opinion on how physicians should test for BRCA in pancreatic cancer patients
Philip Philip, MD, on the outcomes of the POLO study and its importance to physicians
Dr. Philip, Clinical Professor of Oncology, Wayne State University of Medicine, elaborates on the outcomes of the POLO study and it's importance to physicians
Daneng Li, MD, regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for HCC
Dr. Li, Assistant Clinical Professor, City of Hope, shares thoughts regarding the role of immunotherapy in the neoadjuvant and adjuvant setting for respectable HCC
Daneng Li, MD, shares latest thoughts on checkpoint inhibitors being combines with TKIs
Dr. Li, Assistant Clinical Professor, City of Hope, shares latest thoughts on the combination of checkpoint inhibitors with tyrosine kinase inhibitors
Ryan Corcoran, MD, on the current use of MRD as a valid test for determining GI cancer treatment
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, regarding the current use of MRD as a valid test for determining treatment approaches in gastrointestinal cancers
Ryan Corcoran, MD, explains the need for the MRD test in CRC and whether its ready for prime time
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, explains reasoning behind the need for the MRD test in colorectal cancer and whether it is ready for prime time
Ryan Corcoran, explains cell free DNA and ways to test for it
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, explains cell free DNA and ways to test for it
Richard Kim, MD, on results of phase 1 study regarding locally advanced rectal adenocarcioma
Dr. Kim, Professor of Medicine, University of South Florida College of Medicine, shares results of the phase 1 study regarding preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma
Richard Kim, MD, explains how "sided-ness" affects usage of EGFR inhibitors in the treatment of CRC
Dr. Kim, Professor of Medicine, University of South Florida College of Medicine, explains how recent clinical studies concerning "sided-ness" affected his practice in the use of EGFR inhibitors in the treatment of colorectal cancer
Richard Kim, MD, on the combination of cabozantinib and checkpoint inhibitors to improve HCC outcomes
Dr. Kim, Professor of Medicine, University of South Florida College of Medicine, refers to the Checkmate 040 study regarding the combination of cabozantinib with checkpoint inhibitors to improve outcomes when treating second line HCC patients
Benjamin Weinberg, comments on the use of intratumoral microbiome assessment vs GI tract assessment
Dr. Weinberg, Assistant Professor, Medstar Georgetown University Hospital, comments on the intratumoral microbiome assessment versus the assessment of the microbiome of the gastrointestinal tract
Benjamin Weinberg, MD, on the microbiome and the development of colorectal malignancies
Dr. Weinberg, Professor of Medicine, Georgetown University Hospital, explains the relationship between the microbiome and the development of certain colorectal malignancies
Benjamin Weinberg, MD, on demographic results associated with the microbiome and CRC
Dr. Weinberg, Professor of Medicine, Georgetown University Hospital, describes possible demographic or histologic features associated with findings within the microbiome of patients with colorectal cancer
Philip Philip, MD, provides thoughts on the role of PARP inhibitors in advanced pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University of Medicine, provides thoughts regarding the role of PARP inhibitors in advanced pancreatic cancer
Crystal Denlinger, MD, explains differentiation of treatment of CRC patients based on age
Dr. Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, explains strategies regarding differentiation of treatment in terms of older vs younger colorectal cancer patients
Crystal Denlinger, MD, shares data regarding first line biliary tract cancer patients
Dr Denlinger, Chief, Division of Gastrointestinal Medical Oncology, Fox Chase Cancer Center, shares data she authored and was presented at ASCO GI 2020 regarding first line biliary tract cancer patients
David H Ilson, MD, shares perspective of the IPACS study regarding stage 4 CRC patients
Dr. Ilson, Memorial Sloan Kettering Cancer Center, shares perspective regarding the IPACS (JCOG 1007) randomized study in stage 4 colorectal cancer patients which investigates chemotherapy alone vs resection and chemotherapy
David H Ilson, MD, shares results of the ARTDECO study and it's importance to physicians
Dr. Ilson, Memorial Sloan Kettering Cancer Center, shares results from the ARTDECO study and the reason it is important to physicians
Zev Wainberg, MD, shares results of study regarding gastric and GE cancers presented at ASCO GI
Dr. Wainberg, Co-Director of UCLA GI Oncology Program, Ronald Reagan UCLA Medical Center, shared the results of his study investigating pembrolizumab monotherapy in gastric and GE junction cancers presented at ASGO GI 2020
Ryan Corcoran, MD, elaborates on promising clinical applications of cell free DNA
Dr. Corcoran, Associate Professor of Medicine, Harvard Medical School, elaborates on the promising clinical applications of cell free DNA
Richard Kim, MD, on the outcome on the IMBRAVE 150 study & the possibility of new treatment standard
Dr. Kim, Professor of Medicine, Moffit Cancer Center, describes the IMBRAVE 150 phase 3 study and whether the overall survival outcomes are compelling enough to become a new standard of care in the first line treatment of HCC
Daneng Li, MD, on combining cabozantinib with checkpoint inhibitors to improve patient outcomes
Dr. Li, Assistant Clinical Professor, shares thoughts regarding advanced HCC patient improvement by combining cabozantinib with checkpoint inhibitors
Richard Kim, MD determines whether checkpoint inhibitors combine with regorafenib for HCC treatment
Dr. Kim, Professor of Medicine, Moffitt Cancer Center, determines whether checkpoint inhibitors such as pembrolizumab can be combined with regorafenib to treat advanced HCC
Daneng Li, MD, on impressions of patient reported outcomes from the IMBRAVE 150 study
Dr. Li, Assistant Clinical Professor, City of Hope, shares his impressions of the IMBRAVE 150 study particularly relating to patient reported outcomes presented at ASCO GI 2020
Hani Babiker, MD, elaborates on tumor treatment fields applying to GI malignancies
Dr. Babiker, Assistant Director, University of Arizona Cancer Center, explains how treatment fields apply to gastrointestinal malignancies
Hani Babiker, MD, describes the setting of FDA approval on tumor treatment fields
Dr. Babiker, Assistant Director, University of Arizona Cancer Center, describes the setting of FDA approval on tumor treatment fields
Ahmed Kaseb, MD, on combining cabozantinib with checkpoint inhibitors for treatment of HCC
Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, discusses the combination of cabozantinib with checkpoint inhibitors to improve outcomes when treating first line HCC patients.
Ahmed Kaseb, MD, on survival outcomes in the IMBRAVE 150 phase 3 study
Dr. Kaseb, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, on the survival outcomes in the IMBRAVE 150 phase 3 study and whether it is compelling enough to be a new standard of care in the first line treatment of HCC
Nevena Damjanov, MD, on impressions of the study combining cabozantinib with checkpoint inhibitors in advanced HCC patients
Dr. Damjanov, Director of Gastrointestinal Oncology, University of Pennsylvania, on her impressions of the study presented at ASCO which combines cabozantinib with checkpoint inhibitors in advanced HCC patients
Nevena Damjanov, MD, elaborates on the role of TKIs in managing 2nd line HCC patients
Dr. Damjanov, Director of Gastrointestinal Oncology, University of Pennsylvania, discusses her thoughts on the role of TKIs in managing 2nd line HCC patients
Nevena Damjanov, MD, explains the outcomes of combining atezolizumab with bevacizumab in 1st line HCC patients
Dr. Damjanov, Director of Gastrointestinal Oncology, University of Pennsylvania, explains the outcomes of combining atezolizumab with bevacizumab in first line HCC patients presented at ASCO GI 2020
Eileen O'Reilly, MD, on the phase 2 study comparing chemo with or without veliparib in pancreas
Dr. O'Reilly, Winthrop Rockefeller Endowed Chair in Medical Oncology, Memorial Sloan Kettering Center, shares perspective on the phase 2 study comparing gemcitabine/cisplatin with or without veliparib in germ-line pancreatic cancer patients
Eileen O'Reilly, MD, provides evidence to inform treatment of pancreatic cancer patients
Dr. O'Reilly, Winthrop Rockefeller Endowed Chair in Medical Oncology, Memorial Sloan Kettering Cancer Center, provides evidence to inform treatment and management of pancreatic cancer patients
Manish Shah, MD, regarding the use of liquid biopsy to diagnose and treat GI cancers
Dr. Shah, Director, Weill Cornell Medicine, regarding the use of liquid biopsy to diagnose and treat gastrointestinal cancers
Manish Shah, MD, on the role of Cyramza in the treatment of gastric and esophageal cancers
Dr. Shah, Director, Weill Cornell Medicine, discusses the role of Cyramza (ramucirumab) in the treatment of gastric and esophageal cancers
Daniel Catenacci, MD, discusses margetuximab in the treatment of esophageal and gastric cancer
Dr. Catenacci, Associate Professor, The University of Chicago Medical Center and Biological Sciences, on the role of margetuximab in the treatment of esophageal and gastric cancer
Daniel Catenacci, MD, elaborates on the outcomes of the JAVELIN 100 study presented at ASCO GI 2020
Dr. Catenacci, Associate Professor, The University of Chicago Medical Center and Biological Sciences, elaborates on the need for quick responses and immunotherapy in gastroesophageal cancer patients discussed in the Javelin 100 study being presented at ASCO GI 2020
Richard Finn, MD, outlines the role of TACE with systemic therapy in HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, outlines the role of TACE with systemic therapy in hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, on the use of biomarkers in the treatment of esophagogastric cancer
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about reliable biomarkers that should be used when treating esophagogastric cancers
Richard Finn, MD, considers the effectiveness of sorafenib + I-O in newly diagnosed HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, offers opinion on whether sorafenib is effective and tolerable in combination with I-O in newly diagnosed hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, summarizes the role of I-O in esophagogastric cancer treatment algorithms
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, considers the role of evidence-based medicine and the incorporation of I-O into esophagogastric cancer treatment algorithms
John Strickler, MD, shares thoughts on molecular subtyping of pancreatic cancer
Dr. Strickler, MD, Assistant Professor of Medicine, Duke Cancer Institute, considers the good news and the bad news regarding molecular subtyping of pancreatic cancer
John Strickler, MD, on how next-generation sequencing fits into treatment of mCRC
Dr. Strickler, Assistant Professor of Medicine, Duke Cancer Institute, offers his opinion on how next-generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC)
John Strickler, MD, regarding pembrolizumab vs. chemotherapy in 2nd line advanced esophageal cancer
Dr. Strickler, Assistant Professor of Medicine, Duke Cancer Institute, offers his impressions of the study presented at the 2019 Gastrointestinal Cancers Symposium investigating pembrolizumab versus standard chemotherapy in 2nd line advanced esophageal cancer
John Strickler, MD, on combo pembrolizumab, trastuzumab, capecitabine & oxaliplatin in mEGA
Dr. Strickler, Assistant Professor of Medicine, Duke Cancer Institute, considers whether the combination of pembrolizumab, trastuzumab, capecitabine and oxaliplatin is effective in HER2+ metastatic esophagogastric adenocarcinoma (mEGA)
Raymond Wadlow, MD, on surrogate biomarkers in the treatment of hepatocellular carcinoma
Dr. Wadlow, Medical Oncologist, Virginia Cancer Specialist, discusses surrogate biomarkers in the treatment of hepatocellular carcinoma (HCC)
Richard Finn, MD, elaborates on current treatment options & sequencing of TKIs in HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, shares what physicians should know about current treatment options and sequencing of TKIs in hepatocellular carcinoma (HCC)
Zev Wainberg, MD, regarding the results of the ROAR basket trial from GI 2019
Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, tells us about the results of the Phase 2 ROAR basket trial investigating the efficacy and safety of dabrafenib and trametinib in patients with BRAF V600E-mutated biliary tract cancer
Raymond Wadlow, MD, speculates on the use of TKIs in the management of HCC
Dr. Wadlow, Medical Oncologist, Virginia Cancer Specialist, speculates on the use of TKIs in the management of hepatocellular carcinoma (HCC)
Zev Wainberg, MD, considers regorafenib in locally advanced biliary tract cancer
Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, considers the Phase 2 REACHIN study investigating regorafenib in locally advanced biliary tract cancer
David Ilson, MD, PhD, on pembrolizumab, trastuzumab, capecitabine & oxaliplatin in HER2+ mEGA
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on the effectiveness of the combination of pembrolizumab, trastuzumab, capecitabine and oxaliplatin in HER2+ metastatic esophagogastric adenocarcinoma (mEGA)
Raymond Wadlow, MD, regarding BSC vs. combination checkpoint inhibitors in advanced CRC
Dr. Wadlow, Medical Oncologist, Virginia Cancer Specialist, provides his impression of the Phase 2 study presented at the 2019 Gastrointestinal Cancers Symposium investigating BSC versus combination checkpoint inhibitors in advanced colorectal cancer (CRC)
Zev Wainberg, MD, on checkpoint inhibition with chemotherapy in pancreatic cancer
Dr. Wainberg, Co-Director, UCLA Gastro-Intestinal Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, offers his opinion on the Phase I study investigating checkpoint inhibition with standard chemotherapy in pancreatic cancer from GI 2019
Raymond Wadlow, MD, on the outcomes of Keynote 181 in esophageal cancer
Dr. Wadlow, Medical Oncologist, Virginia Cancer Specialist, tell us about Keynote 181 presented at the 2019 Gastrointestinal Cancers Symposium
Bassel El-Reyes, MD, speculates on promising novel therapies being developed for pancreatic cancer
Dr. El-Reyes, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Emory University School of Medicine, John Kauffman Family Professor for Pancreatic Cancer Research, Winship Cancer Institute of Emory University, speculates on the most promising novel therapies being developed for pancreatic cancer
Bassel El-Reyes, MD, considers upfront surgery for resectable pancreatic cancer
Dr. El-Reyes, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Emory University School of Medicine, John Kauffman Family Professor for Pancreatic Cancer Research, Winship Cancer Institute of Emory University, explains how neoadjuvant chemotherapy with gemcitabine and S-1 compares with upfront surgery for resectable pancreatic cancer
Martine Extermann, MD, PhD, on identifying the right treatment for patients with gastric cancer
Dr. Extermann, Program Leader, Senior Adult Oncology, Moffitt Cancer Center, shares her thoughts on identifying the right treatment for patients with gastric cancer
Bassel El-Reyes, MD, offers his opinion on NGS & BRCA gene testing for pancreatic cancer
Dr. El-Reyes, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Emory University School of Medicine, John Kauffman Family Professor for Pancreatic Cancer Research, Winship Cancer Institute of Emory University, offers his opinion on next-generation sequencing (NGS) and BRCA gene testing for pancreatic cancer
Martine Extermann, MD, PhD, shares the results of the FOLFOX +/- andecaliximab study from GI '19
Dr. Extermann, Program Leader, Senior Adult Oncology, Moffitt Cancer Center, shares the results of the Phase 3 study investigating FOLFOX +/- andecaliximab study in advanced gastric or GEJ cancer
Bassel El-Reyes, MD, regarding molecular subtyping of pancreatic cancer
Dr. El-Reyes, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Emory University School of Medicine, John Kauffman Family Professor for Pancreatic Cancer Research, Winship Cancer Institute of Emory University, shares the good news and the bag news regarding molecular subtyping of pancreatic cancer
Martine Extermann, MD, PhD, on the investigation of TAS-102 in metastatic gastric cancer
Dr. Extermann, Program Leader, Senior Adult Oncology, Moffitt Cancer Center, tells us about the results of the Phase 3 study investigating TAS-102 in metastatic gastric cancer presented at the 2019 Gastrointestinal Cancers Symposium
Bassel El-Reyes, MD, on screening patients at high risk for pancreatic cancer
Dr. El-Reyes, Professor and Vice Chair for Clinical Research, Department of Hematology and Medical Oncology, Emory University School of Medicine, John Kauffman Family Professor for Pancreatic Cancer Research, Winship Cancer Institute of Emory University, offers his opinion on whether we should be routinely screening patients at high risk for pancreatic cancer
Richard Finn, MD, speculates on combined checkpoint inhibition in HCC & biliary tract cancer
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, UCLA, considers how combined checkpoint inhibition could potentially change treatment algorithms in advanced hepatocellular carcinoma (HCC) and biliary tract carcinoma
David Ilson, MD, PhD, compares pembrolizumab & chemotherapy in advanced esophageal cancer
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on how pembrolizumab compares with chemotherapy as a 2nd line therapy for advanced esophageal cancer
Richard Finn, MD, shares his thoughts on the role of systemic therapy in HCC
Dr. Finn, Professor of Clinical Medicine, Department of Medicine, Division of Hematology/ Oncology, Geffen School of Medicine, UCLA, considers the role of systemic therapy in the management of hepatocellular carcinoma (HCC)
David Ilson, MD, PhD, shares results from the TAGS trial presented at GI 2019
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about the results of the Phase 3 study investigating TAS-102 in metastatic gastric cancer presented the 2019 Gastrointestinal Cancers Symposium
Rachna Shroff, MD, gives her take on pre-operative therapy in resectable pancreatic cancer
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, considers the role of pre-operative therapy in resectable pancreatic cancer
Richard Kim, MD, regarding the use of regorafenib in treatment of colorectal cancer
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, offers his opinion on whether physicians are likely to dose escalate with regorafenib when treating colorectal cancer (CRC)
Rachna Shroff, MD, on the utilization of TKIs in treatment of hepatocellular carcinoma
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, on the evolving treatment landscape of hepatocellular carcinoma (HCC), specifically regarding the use of TKIs in managing the disease
Richard Kim, MD, shares how we can utilize TKIs in the management of hepatocellular carcinoma
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, provides opinion on utilizing TKIs in the management of hepatocellular carcinoma (HCC)
Rachna Shroff, MD, discusses how BRAF mutations figure into cholangiocarcinoma treatment
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, elaborates on how BRAF mutations figure into treatment algorithms for cholangiocarcinoma
Rachna Shroff, MD, expands on targeted therapies in the treatment of cholangiocarcinoma
Dr. Shroff, Chief, Section of GI Medical Oncology, Associate Professor of Medicine, Division of Hematology/Oncology, University of Arizona Cancer Center, tells us how targeted therapies are being integrated into the treatment of cholangiocarcinoma
Richard Kim, MD, on the role of BRAF mutations in treatment of cholangiocarcinoma
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, explains how the BRAF mutation figures into treatment algorithms for cholangiocarcinoma
Richard Kim, MD, regarding targeted therapies in treatment of cholangiocarcinoma
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, tells us how targeted therapies are being integrated into the treatment of cholangiocarcinoma
Andrew X. Zhu, MD, PhD, considers whether sorafenib is tolerable in combination with I-O in HCC
Dr. Zhu, Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, considers whether sorafenib is tolerable in combination with I-O in newly diagnosed hepatocellular carcinoma (HCC) patients
Andrew X. Zhu, MD, PhD, on what physicians should know about sequencing TKIs in HCC
Dr. Zhu, Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, provides opinion on what physicians should know about sequencing TKIs in hepatocellular carcinoma (HCC) patients
Andrew X. Zhu, MD, PhD, regarding checkpoint inhibitors in advanced HCC
Dr. Zhu, Professor, Department of Medicine, Harvard Medical School, Director, Liver Cancer Research, Medicine, Massachusetts General Hospital, considers how checkpoint inhibitors could potentially change treatment algorithms in advanced hepatocellular carcinoma (HCC)
Axel Grothey, MD, on the CCTG CO.26 trial in advanced refractory CRC presented at GI 2019
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares his impression of the CCTG CO.26 trial comparing durvalumab plus tremelimumab and best supportive care (BSC) versus BSC in advanced refractory colorectal cancer (CRC)
Alan Venook, MD, shares key takeaways from GI 2019 regarding the treatment of biliary tract cancers
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, on the takeaways from the 2019 Gastrointestinal Cancers Symposium regarding treatment of biliary tract cancers
Axel Grothey, MD, on the use of regorafenib in the management of advanced CRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, considers whether the results of ReDOS study have allowed for more effective dosing of regorafenib in the management of advanced colorectal cancer (CRC) patients
Alan Venook, MD, on the latest in identifying valid biomarkers in the treatment of HCC
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, shares the latest in identifying valid biomarkers in the treatment of hepatocellular carcinoma (HCC)
Axel Grothey, MD, on patient selection & treatment algorithms in 2nd and 3rd line CRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, shares details regarding patient selection and treatment algorithms in the management of 2nd and 3rd line colorectal cancer patients
Alan Venook, MD, tells us whether ctDNA is a valid treatment response in CRC
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, tells us whether circulating tumor DNA (ctDNA) is a valid surrogate for minimal residual disease (MRD) or treatment response in colorectal cancer
Axel Grothey, MD, considers the role of circulating tumor DNA (ctDNA)
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, on whether circulating tumor DNA (ctDNA) is a valid surrogate for minimal residual disease (MRD) or treatment response in colorectal cancer
Alan Venook, MD, discusses next generation sequencing and mCRC treatment
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, provides opinion on how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Axel Grothey, MD, elaborates on next generation sequencing and mCRC
Dr. Grothey, Consultant, West Cancer Center, University of Tennessee, explains how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Philip Philip MD, PhD, FRCP, on neoadjuvant chemotherapy & upfront surgery in pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, explains how neoadjuvant chemotherapy with gemcitabine and S-1 compares with upfront surgery for resectable pancreatic cancer
Philip Philip MD, PhD, FRCP, on promising novel therapies for pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the most promising novel therapies in the pipeline for pancreatic cancer
Nevena Damjanov, MD, regarding the impact of the ReDOS study in HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, considers whether physicians are more likely to use regorafenib and dose escalate for hepatocellular carcinoma (HCC) patients as a result of the ReDOS study
Philip Philip MD, PhD, FRCP, provides opinion on NGS and BRCA gene testing in pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, on whether he recommends next generation sequencing (NGS) or BRCA gene testing for pancreatic cancer patients
Nevena Damjanov, MD, elaborates on stereotactic body radiation therapy in early stage HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, explains how stereotactic body radiation therapy (SBRT) is being used to treat early stage hepatocellular carcinoma (HCC)
Philip Philip MD, PhD, FRCP, considers molecular subtyping of pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, describes the good news and the bad news regarding molecular subtyping of pancreatic cancer
Nevena Damjanov, MD, regarding sequencing TKIs in hepatocellular carcinoma (HCC)
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania tells us what physicians should know about current treatment options and sequencing TKIs in hepatocellular carcinoma (HCC)
Philip Philip MD, PhD, FRCP, on screening patients at high risk for pancreatic cancer
Dr. Philip, Professor of Oncology, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, provides opinion on whether we should routinely screen patients at high risk for pancreatic cancer
Nevena Damjanov, MD, shares thoughts on the role of systemic therapy in HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, considers whether systemic therapy still plays a role in the management of hepatocellular carcinoma (HCC)
Jeffrey A. Meyerhardt, MD, on genetic testing in newly diagnosed mCRC
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, shares thoughts on genetic testing in newly diagnosed metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, on how checkpoint inhibitors are impacting treatment algorithms in mCRC
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, explains how checkpoint inhibitors are impacting treatment algorithms in metastatic colorectal cancer (mCRC)
Jeffrey A. Meyerhardt, MD, shares thoughts on checkpoint inhibitors in adjuvant CRC
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute offers opinion on whether checkpoint inhibitors will be successful in improving outcomes for adjuvant colorectal cancer (CRC) patients
Howard Hochster, MD, considers next generation sequencing and mCRC treatment decisions
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, considers how next generation sequencing (NGS) fits into diagnosis and treatment of metastatic colorectal cancer (mCRC) patients
Jeffrey A. Meyerhardt, MD, on managing 2nd and 3rd line mCRC patients
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, tells us how he manages 2nd and 3rd line metastatic colorectal cancer (mCRC) patients and shares some of the drivers of treatment choice
Howard Hochster, MD, on the management of mCRC patients receiving regorafenib
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, discusses the results of the ReDose study and the management of metastatic colorectal cancer (mCRC) patients receiving regorafenib
Jeffrey A. Meyerhardt, MD, on whether regorafenib is becoming more tolerable for mCRC patients
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, considers whether the results of the ReDOS study may make dosing of regorafenib more tolerable for metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, explains how to manage 2nd and 3rd line mCRC patients
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, describes how he manages 2nd and 3rd line metastatic colorectal cancer (mCRC) patients
Jeffrey A. Meyerhardt, MD, considers the BEACON study in BRAF mutated metastatic colorectal cancer
Dr. Meyerhardt, Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, discusses the BEACON study investigating the role of encorafenib, binimetinib and cetuximab in patients with BRAF mutated metastatic colorectal cancer (mCRC)
Howard Hochster, MD, regarding the role of genetic testing in mCRC
Dr. Hochster, Associate Director for Clinical Research, Rutgers Cancer Institute of New Jersey, Director of Oncology Research, RWJBarnabas Health, elaborates on genetic testing in newly diagnosed metastatic colorectal cancer (mCRC) patients and how these tests figure into treatment decisions
Steven J. Cohen, MD, outlines the results of the Checkmate 142 study in mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, tells us about the results of the Checkmate 142 study comparing Yervoy (ipilimumab) + Opdivo (nivolumab) in metastatic colorectcal (mCRC) patients
Steven J. Cohen, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, provides insight into sequencing and efficacy outcomes in 2nd line mCRC
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, compares sequencing Stivarga (regorafenib) followed by Erbitux (cetuximab) with the reverse sequence in terms of efficacy outcomes in 2nd line metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, describes how tumor sidedness impacts treatment decisions in mCRC
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, tells us how tumor sidedness affects treatment decisions in metastatic colorectal cancer (mCRC)
Steven J. Cohen, MD, regarding combination atezolizumab + cobimetinib in mCRC patients
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, elaborates on whether the combination of Tecentriq (atezolizumab) and Cotellic (cobimetinib) is effective in treatment of metastatic colorectal cancer (mCRC) patients
Steven J. Cohen, MD, considers the improvement in duration of therapy examined in the ReDOS study
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, discusses the importance of the improvement in duration of therapy as examined in the ReDOS study
Steven J. Cohen, MD, on how to dose patients receiving regorafenib as a result of the ReDOS study
Dr. Cohen, Chief, Medical Oncology & Hematology Division, Jefferson Health/Abington Hospital Vice-Chair, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, explains how to consider dosing patients receiving Stivarga (regorafenib) as a result of the ReDOS study
Michael Soulen, MD, discusses the most compelling presentations from ASCO GI 2018
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, offers his opinion on the most compelling data coming out of ASCO GI 2018
Michael Soulen, MD, compares the possible benefits of retrospective vs. prospective trials
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, considers the benefits of retrospective versus prospective trials in resectable and unresectable metastatic neuroendocrine tumors
Michael Soulen, MD, on the practice changing potential of data presented at his ASCO GI tumor board
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, elaborates on how data presented at his ASCO GI tumor board session has the potential to be practice changing
Michael Soulen, MD, tells us about significant data coming out of the tumor board at ASCO GI 2018
Dr. Soulen, Professor of Radiology, Hospital of the University of Pennsylvania, Professor of Radiology in Surgery, Penn Medicine, shares significant data and conclusions from his ASCO GI 2018 tumor board
Philip Philip, MD, PhD, FRCP, discusses the impact of the Checkmate 142 study on mCRC
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the importance of the Checkmate 142 study (ipilimumab + nivolumab) for metastatic colorectal cancer (mCRC) and how it may impact future therapies
Philip Philip, MD, PhD, FRCP, on the implications of the LAPACT study presented at ASCO 2018
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, offers opinion on the results of the LAPACT study and whether adding nab-paclitaxel to gemcitabine improves efficacy for locally advanced pancreatic cancer patients
Philip Philip, MD, PhD, FRCP, considers the impact of immunotherapy agents in pancreatic cancer
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, discusses the role of immunotherapy agents in pancreatic cancer and whether they have an impact on treatment outcome
Philip Philip, MD, PhD, FRCP, regarding key unmet needs in pancreatic ductal adenocarcinoma
Dr. Philip, Professor of Medicine, Wayne State University School of Medicine, Clinical Professor of Oncology, Barbara Ann Karmanos Cancer Institute, elaborates on the key unmet needs in treating pancreatic ductal adenocarcinoma
Nevena Damjanov, MD, shares the latest news in systemic therapy for advanced HCC at ASCO 2018
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, tells us about the exciting news in systemic therapy for advanced hepatocellular carcinoma (HCC) coming out of ASCO GI 2018
Nevena Damjanov, MD, on the use of pembrolizumab in HCC patients previously treated with sorafenib
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, offers opinion on whether Keytruda (pembrolizumab) is effective in hepatocellular carcinoma (HCC) patients that have been previously treated with Nexavar (sorafenib)
Nevena Damjanov, MD, outlines the role of TACE with systemic therapy in HCC patients
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, explains the role of TACE with systemic therapy in hepatocellular carcinoma (HCC) patients
David Ilson, MD, PhD, considers how to assess response in gastroesophageal cancer patients
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, elaborates on how to assess response in gastroesophageal cancer patients
Richard Kim, MD, offers opinion on the ReDOS study and dose escalation of regorafenib
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, regarding the ReDOS study and whether, as a result, physicians are more likely to use Stivarga (regorafenib) and dose escalate for hepatocellular carcinoma (HCC) patients & metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, on the potential of binimetinib + immunotherapy in mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on whether adding binimetinib to immunotherapies improves overall response rates in metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, regarding molecular profile matching in trials with mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses whether molecular profile matching improves outcomes in clinical trials with metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, elaborates on the outcomes of the BEACON Phase 3 study investigating the triple combination of encorafenib, binimetinib, and cetuximab in BRAF-mutant metastatic colorectal cancer (mCRC) patients and how this compares to prior data
Jeffrey Meyerhardt, MD, MPH, on dose escalation of regorafenib as a result of the ReDOS study
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, on the results of the ReDOS study and whether, as a result, physicians should feel comfortable using dose escalation of Stivarga (regorafenib)
Jeffrey Meyerhardt, MD, MPH, discusses the length of adjuvant therapy for colorectal cancer patients
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, analyzes whether three months of adjuvant therapy is enough for colorectal cancer (CRC) patients
Jeffrey Meyerhardt, MD, MPH, on the implications of the BEACON Phase 3 study in BRAF-mutant mCRC
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, elaborates on the outcomes of the BEACON Phase 3 study investigating the triple combination of encorafenib, binimetinib, and cetuximab in BRAF-mutant metastatic colorectal cancer (mCRC) patients
Jeffrey Meyerhardt, MD, MPH, considers the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Meyerhardt, Associate Professor, Medicine, Harvard Medical School, Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Nevena Damjanov, MD, discusses current treatment options and sequencing TKIs in HCC
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, provides insight into what physicians should know about current treatment options and sequencing TKIs in hepatocellular carcinoma (HCC) patients
Nevena Damjanov, MD, considers the shortcomings of RECIST in measuring efficacy in HCC patients
Dr. Damjanov, Chief of GI Oncology, Abramson Cancer Center at Penn Presbyterian, University of Pennsylvania, elaborates on the shortcomings of RECIST in measuring efficacy in hepatocellular carcinoma (HCC ) patients
Scott Kopetz, MD, PhD, FACP, explains how nivolumab is being incorporated into mCRC treatment
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, shares how Opdivo (nivolumab) is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms
Scott Kopetz, MD, PhD, FACP, tells us about the outcomes of Checkmate 142 in mCRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, outlines the results of the Checkmate 142 study looking at Yervoy (ipilimumab) and Opdivo (nivolumab) in metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, considers the addition of vemurafenib to the NCCN guidelines for mCRC
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the patient type and setting where Zelboraf (vemurafenib) has been added to the NCCN guidelines for metastatic colorectal cancer (mCRC) patients
Scott Kopetz, MD, PhD, FACP, discusses the incidence of BRAF mutation in CRC patients
Dr. Kopetz, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, analyzes the incidence of BRAF mutation in colorectal cancer (CRC) patients and what this means for treatment outcomes
Richard Kim, MD, offers analysis of the RAINFALL study in metastatic gastric & GE junction cancer
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, discusses the RAINFALL study results in metastatic gastric and GE junction cancer patients and the implications for physicians
Richard Kim, MD, discusses pembrolizumab as an effective agent in HCC management
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, elaborates on Keytruda (pembrolizumab) as an agnet in the management of hepatocellular carcinoma (HCC) patients
Richard Kim, MD, considers the effectiveness of combination sorafenib and TACE in HCC patients
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, on whether it is effective to combine Nexavar (sorafenib) with TACE in hepatocellular carcinoma (HCC) patients
Richard Kim, MD, on the use and sequencing of TKIs in hepatocellular carcinoma (HCC)
Dr. Kim, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine, describes how TKIs should be used in 1st line hepatocellular carcinoma (HCC) and how TKIs should be sequenced for the disease at this time
David Ilson, MD, PhD, discusses what can be done to improve outcomes in esophageal adenocarcinoma
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, on what can be done to improve outcomes in esophageal adenocarcinoma patients
David Ilson, MD, PhD, examines the results of the RAINFALL study at ASCO GI 2018
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, tells us about the results of the RAINFALL study in 1st line metastatic gastric or GE junction cancer patients
David Ilson, MD, PhD, on strategies for managing gastroesophageal patients after neoadjuvant therapy
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, outlines strategies for managing gastroesophageal patients who have had a complete response after neoadjuvant therapy
David Ilson, MD, PhD, on how we can individualize treatment of gastroesophageal cancer patients
Dr. Ilson, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, offers opinion on how management of gastroesophageal cancer patients can be individualized
Howard Hochster, MD, outlines the results of the Checkmate 142 study in mCRC patients
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, tells us about the results of the Checkmate 142 study comparing Yervoy (ipilimumab) + Opdivo (nivolumab) compared to Yervoy (ipilimumab) alone in metastatic colorectcal (mCRC) patients
Howard Hochster, MD, considers patient age and the OncotypeDX recurrence score in CRC
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, on whether patient age impacts the reliability of the OncotypeDX recurrence score in colorectal cancer (CRC) patients
Andrew Zhu, MD, PhD, on the effectiveness of pembrolizumab in HCC patients treated with sorafenib
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, considers whether Keytruda (pembrolizumab) is effective in hepatocellular carcinoma (HCC) patients who have been previously treated with Nexavar (sorafenib)
Andrew Zhu, MD, PhD, shares thoughts on treating adjuvant hepatocellular carcinoma (HCC) today
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, elaborates on how to treat adjuvant hepatocellular carcinoma (HCC) today
Laura Dawson, MD, FRCPC, on additional randomized studies of external beam radiation
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, outlines additional randomized studies of external beam radiation
Laura Dawson, MD, FRCPC, tells us about the results of the START study
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, shares the results of the START study comparing transarterial chemoembolization plus external beam radiotherapy to Nexavar (sorafenib)
Laura Dawson, MD, FRCPC, discusses the design of the START study in HCC
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, elaborates on the design of the START study in hepatocellular carcinoma (HCC)
Laura Dawson, MD, FRCPC, provides some background on hepatocellular carcinoma (HCC)
Dr. Dawson, Professor, Department of Radiation Oncology, University of Toronto, on hepatocellular carcinoma (HCC) and why this patient population is particularly challenging to treat
Alan Venook, MD, outlines the role of liquid biopsy in gastrointestinal cancers
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, discusses the role of liquid biopsy in gastrointestinal cancers
Alan Venook, MD, considers how immunotherapy is being integrated into CRC treatment algorithms
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, describes how immunotherapy is being integrated into colorectal cancer (CRC) treatment algorithms
Alan Venook, MD, on the impact of dose escalation of regorafenib in mCRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, explains how dose escalation of Stivarga (regorafenib) in metastatic colorectal cancer (mCRC) patients impacts efficacy and tolerability
Alan Venook, MD, discusses vemurafenib and the NCCN guidelines for mCRC patients
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, on the patient type and setting where Zelboraf (vemurafenib) has been added to the NCNN guidelines for metastatic colorectal cancer (mCRC) patients
Alan Venook, MD, explains how tumor sidedness affects therapeutic choice
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF, describes how tumor sidedness impacts therapeutic choice
Khaldoun Almhanna, MD, MPH, offers opinion on the best way to manage early gastric cancer
Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, considers the best way(s) to manage early gastric cancer
Khaldoun Almhanna, MD, MPH, discusses the risk factors to watch for gastroesophageal cancer
Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, elaborates on some of the risk factors for gastroesophageal cancer that physicians should be on the lookout for
Kenneth Wang, MD, offers opinion on approaches to treating esophageal cancer
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, tells us what approach or approaches to treating esophageal cancer might deliver the best outcomes in the future
Kenneth Wang, MD, on managing esophageal cancer patients who have completed neoadjuvant therapy
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, describes how he manages esophageal cancer patients that have had a complete response to neoadjuvant therapy
Kenneth Wang, MD, on how to assess response in esophageal cancer and utilize the information
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, offers opinion on the best way to assess response in esophageal cancer and what should be done with the information
Howard Hochster, MD, elaborates on how tumor sidedness affects therapeutic choice in mCRC patients
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, shares thoughts on how tumor sidedness affects therapeutic choice in metastatic colorectal cancer (mCRC) patients
Howard Hochster, MD, on the ReDOS study, regorafenib, and the importance of duration of therapy
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, considers the ReDOS study and how 20% of patients remained on Stivarga (regorafenib) for 6+ months
Andrew Zhu, MD, PhD, shares the latest in systemic therapy for advanced HCC at ASCO GI 2018
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, elaborates on the latest in systemic therapy for advanced hepatocellular carcinoma (HCC) at ASCO GI 2018
Andrew Zhu, MD, PhD, on how we diagnose and assess response in HCC patients
Dr. Zhu, Professor of Medicine, Harvard Medical School, Director, Liver Cancer Research, explains how we diagnose and assess response in hepatocellular carcinoma (HCC) patients
Khaldoun Almhanna, MD, MPH, on surveillance and the management of gastroesophageal cancer
Dr. Almhanna, Department of Gastrointestinal Oncology, Moffitt Cancer Center, Associate Professor of Oncology, University of South Florida College, describes how surveillance is impacting the management of gastroesophageal cancer
Kenneth Wang, MD, considers how staging esophageal cancer has changed and improved
Dr. Wang, Director of Advanced Endoscopy Group & Esophageal Neoplasia Clinic, Consultant, Division of Gastroenterology and Hematology, explains how staging esophageal cancer has changed and improved over time
Howard Hochster, MD, offers opinion on the ReDOS study and dose escalation of regorafenib
Dr. Hochster, Professor of Medicine, Medical Oncology Section of Solid Tumor Oncology, Robert Wood Johnson Medical School, Rutgers, discusses the outcomes of the ReDOS study and whether physicians should feel comfortable using dose escalation of Stivarga (regorafenib) in their practice
Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study
Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the results of the NETTER-1 study
Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study
Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the quality of life data from the NETTER-1 study
John L. Marshall, MD, talks about the results of the RESORCE trial
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, talks about the results of the RESORCE trial and how it will impact the treatment of HCC
John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, discusses which molecular tests to order when determining treatment approach in a newly diagnosed CRC patient
John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how to integrate genetic mutations, and left sided vs right sided CRC, into a treatment decision
John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, on how checkpoint inhibitors are being integrated into treatment of GI cancers
John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies
Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, tells us how vaccines can be used to broaden the use of immunotherapies in GI cancer patients
Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, talks about the DFCI wellness study demonstrating that CRC patients with greater physical activity have better outcomes
Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage 4 pancreatic cancer patient
Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on whether resected pancreatic cancer patients should be offered adjuvant therapy
Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, shares his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients
Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on which molecular tests to order for a newly diagnosed CRC patient
Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients
Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on integrating immunotherapy into existing treatment regimens for CRC patients
Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, explains how the 80405 study in CRC patients is impacting on treatment guidelines
Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses which molecular tests to order for a newly diagnosed CRC patient
Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients
Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on identifying subgroups of HCC patients that are more likely to respond to therapy
Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on if the RESORCE trial will change the role of regorafenib in the treatment unresectable HCC
Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens for gastric cancer patients
Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens for HCC patients
Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients
Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens for CRC patients
Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how checkpoint inhibitors will be incorporated into the treatment of unresectable HCC
Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on reliably identifying subgroups of patients for targeted therapies in HCC
Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on whether physicians will incorporate regorafenib into clinical practice
Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017
Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment
Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how new agents being studied for advanced HCC will be integrated into the treatment
Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients
Dr. Hochster, Associate Director, Yale Cancer Center, on integrating immunotherapy into existing treatment regimens for GI cancer patients
Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, explains the outcomes of the randomized phase 2 study in BRAF mutated CRC patients
Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, discusses if genetic profiling has changed the approach to treating CRC patients
Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients
Dr. Hochster, Associate Director, Yale Cancer Center, provides his perspective on how to use both TAS-102 and regorafenib in a metastatic CRC patients, specifically sequencing
Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102
Dr. Hochster, Associate Director, Yale Cancer Center, differentiates regorafenib from 5FU and TAS-102 from a mechanism of action perspective
Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses how checkpoint inhibitors be incorporated into the treatment of unresectable HCC
Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, on identifying subgroups of patients for targeted therapies in HCC
Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, shares his thoughts on whether physicians will incorporate regorafenib into clinical practice
Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, discusses the outcomes of the RESORCE trial
Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment
Dr. Abou-Alfa, Memorial Sloan Kettering Cancer Center, explains how new agents in advanced HCC are being integrated into treatment
Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains how checkpoint inhibitors will be incorporated into the treatment of unresectable HCC
Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses identifying subgroups of patients for targeted therapies in HCC
Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, shares her thoughts on whether physicians will incorporate regorafenib into clinical practice
Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017
Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment
Dr. Damjanov, Chief of GI Oncology at Abramson Cancer Center at Penn Presbyterian, discusses how new agents being studied for advanced HCC will be integrated into the treatment
Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the Proprietary Neoantigen Identification Technology platform
Johanna Bendell, MD, discusses the RESORCE trial data
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, provides her expectations on how the RESORCE trial data will change how this patient population is treated today
Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, discusses some of the challenges in treating pancreatic cancer
Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, shares her thoughts on some exciting trials or drugs in development in pancreatic cancer today
Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017
Johanna Bendell, MD, Director, GI Oncology Research, Sarah Cannon Research Institute, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017
Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains the outcomes of the randomized phase 2 study in BRAF mutated CRC patients
Jeffrey A. Meyerhardt, MD, discusses how consensus molecular subtypes help with CRC treatment
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses how the four consensus molecular subtypes help with CRC treatment decisions
Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, explains which molecular tests help determine treatment approach
Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer
Dr. Meyerhardt, Associate Professor of Medicine, Dana Farber Cancer Institute, discusses integrating immunotherapy into existing treatment regimens for GI cancer patients
Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, discusses the goals of the NCI-MATCH trial and the progress to date
Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how the Blue Ribbon Panel may help with the Cancer Moonshot initiative
Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, talks about how integrating immunotherapy into existing treatment regimens for CRC patients
Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research
Dr. Mitchell, Clinical Professor of Medicine, Thomas Jefferson University, explains how organoids are being used for cancer biology research
Choosing which EGFR inhibitor to use in second line treatment of mCRC patients At ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses which EGFR inhibitor to use in second line treatment of mCRC patients at ASCO GI 2016.
TAS-102 versus 5-flourouracil and other more familiar agents ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses TAS-102 versus 5-flourouracil and other more familiar agents at ASCO GI 2016.
RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE versus CORRECT and CONCUR trials evaluating regorafenib in metastatic CRC at ASCO GI 2016.
RECOURSE trial did performance status impact benefit from TAS-102 at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses RECOURSE trial and if performance status impact benefit from TAS-102 at ASCO GI 2016.
Integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses integrating TAS-102 and regorafenib into your therapeutic algorithm for advanced CRC at ASCO GI 2016.
Design of the RECOURSE trial on which the FDA approved TAS-102
Axel Grothey, MD of Mayo Clinic discusses the design of the RECOURSE trial on which the FDA approved TAS-102 at ASCO GI 2016.
RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC
Axel Grothey, MD of Mayo Clinic discusses the RECOURSE trial compared to CORRECT and CONCUR evaluating regorafenib in mCRC at ASCO GI 2016.
Biggest questions facing the treatment of colorectal cancer ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses the biggest questions facing the treatment of colorectal cancer at ASCO GI 2016.
How has the last 10 years changed the way you treat metastatic colorectal cancer ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses how has the last 10 years changed the way you treat metastatic colorectal cancer.
Immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses immunotherapy, MET, and HER 2+ research is the future of colorectal cancer treatment ASCO GI 2016.
Potential cases to use Regorafenib over TAS-102 ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses potential cases to use Regorafenib over TAS-102 ASCO GI 2016.
Regorafenib experience and integrating TAS-102 for advanced CRC ASCO GI 2016
Axel Grothey, MD of Mayo Clinic discusses regorafenib experience and integrating TAS-102 for advanced CRC at ASCO GI 2016.
PD-L1 markers in MMR deficient cancers ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses PD-L1 markers in MMR deficient cancers at ASCO GI 2016.
Mismatch Repair (MMR) deficient and the use of PD-1 blockade ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses Mismatch Repair (MMR) deficient and the use of PD-1 blockade at ASCO GI 2016.
ERCC1 not a valid prognostic or predictive factor in advanced CRC ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how ERCC1 not a valid prognostic or predictive factor in advanced CRC at ASCO GI 2016.
Planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers ASCO Gi 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses planned studies to evaluate immune checkpoint inhibitors in MMR deficient GI cancers at ASCO Gi 2016.
STEAM trial may not change treatment paradigm for metastatic CRC ASCO 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses how the STEAM trial may not change treatment paradigm for metastatic CRC at ASCO 2016.
RAS mutation in patients with metastatic colorectal cancer ASCO GI 2016
David H. Ilson, MD of Memorial Sloan Kettering Cancer Center discusses RAS mutation in patients with metastatic colorectal cancer at ASCO GI 2016.
The future of gastric cancers will be targeted agents including immunotherapy
Manish Shah, MD of Weill-Cornell Medical Center states that the future of gastric cancers will be targeted agents including immunotherapy at ASCO GI 2016.
FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma
Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma at ASCO GI 2016.
Phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma
Joel Randolph Hecht, MD of UCLA Health discusses phase II-III trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
ASCO GI 2016 Optimal Dosage Using Regorafenib Colorectal Cancer
Al B. Benson, MD of Northwestern University discusses the optimal dosage using Regorafenib in colorectal cancer at ASCO GI 2016.
Managing patients on regorafenib including adverse events
Al B Benson, MD of Northwestern University discusses managing patients on regorafenib including adverse events at ASCO GI 2016.
Next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses the next steps for checkpoint inhibitors after Checkmate-032 and KEYNOTE-028 trials in UGI malignancies at ASCO GI 2016.
KEYNOTE-028 results with pembrolizumab
Dr. Dale Shepard, MD, PhD OF Cleveland Clinic discusses KEYNOTE-028 results with pembrolizumab at ASCO GI 2016.
Pembrolizumab looks promising according to KEYNOTE-028 results
Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses Pembrolizumab looks promising according to KEYNOTE-028 results at ASCO GI 2016.
Immunotherapy Shows Promise in MSI-High Colorectal Cancer
Davendra Sohal, MD of Cleveland Clinic discusses promise in MSI-High Colorectal Cancer at ASCO GI 2016.
Pancreatic Cancer News from ASCO GI 2016
Davendra Sohal, MD of Cleveland Clinic discusses Pancreatic Cancer News from ASCO GI 2016.
Weekly T-DM1 surprising or disappointing ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses weekly T-DM1 surprising or disappointing at ASCO GI 2016.
GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses GATSBY trial results T-DM1 in previously treated gastric and GE junction adenocarcinoma at ASCO GI 2016.
Using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses using anti-angiogenic agents in advanced gastric and esophagogastric adenocarcinomas at ASCO GI 2016.
Post-operative adjuvant therapy for resectable patients with node positive oesophageal cancer ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses post-operative adjuvant therapy for resectable patients with node positive esophageal cancer at ASCO GI 2016.
FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016
Daniel Catenacci, MD of The University of Chicago Medicine discusses FOLFOX + ziv-aflibercept v. AVAGAST trial of capecitabine-cisplatin with or without bevacizumab in gastric carcinomas at ASCO GI 2016.
Future of TAS-102 and regorafenib for patients with colorectal cancer
Howard S Hochster, MD of Yale Medical Center discusses the future of TAS-102 and regorafenib for patients with colorectal cancer at ASCO GI 2016.
TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1
Howard S Hochster, MD of Yale Medical Center discusses TAS-102 and how it differ from more familiar agents, such as 5-flourouracil, capecitabine and S-1 at ASCO GI 2016.
RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib
Howard S Hochster, MD of Yale Medical Center discusses RECOURSE trial versus CORRECT and CONCUR trials evaluating regorafenib at ASCO GI 2016.
Importance of performance status prior to starting regorafenib at ASCO GI 2016
Alan P. Venook, MD of University of California San Francisco discusses the importance of performance status prior to starting regorafenib at ASCO GI 2016.
Follow @OBRTweets